NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
University of Miami
Pfizer
Massachusetts General Hospital
Eli Lilly and Company
Karolinska University Hospital
Karolinska University Hospital
Institute of Cancer Research, United Kingdom